News

PFE

3 Top Biopharma Companies for Second Half of 2018

Todd William | Equities.com |

Allergan, Pfizer, and Johnson & Johnson are poised to make big moves.


​Schwab and iShares Funds for Dividend Growth

MoneyShow | Equities.com |

When in doubt, hold a couple of ETFs.


NIH Launches Multi-Organizational Partnership to Advance Parkinson's Disease Clinical Trials

Edward Kim | Equities.com |

To identify and validate promising biomarkers for Parkinson's disease (Image: NIH)


​Why J&J, Pfizer and Amgen Are Strong Pharma Picks

MoneyShow | Equities.com |

Big Pharma has deep pockets, growth through new drugs and price increases and strong balance sheets.


​The Pharma Stocks We’re Buying Now

Vitaliy Katsenelson | Equities.com |

Drumroll, please...


Lilly Gets FDA Approval for Advanced Breast Cancer Treatment

Edward Kim | Equities.com |

New targeted treatment option for certain patients with breast cancer who are not responding to existing therapies (Image: National Cancer Institute).


SpringWorks Therapeutics Spins Out of Pfizer with $103 Million Series A

Edward Kim | Equities.com |

The new spin off will start life with 4 clinical stage candidates.


​Here's The Real Importance Of The Latest Novartis AG (ADR) (NYSE:NVS) News

Mark Collins | Equities.com |

Here's what just happened with Novartis and why it's so important.


​Allergan: Botox and Beyond in Biotech

MoneyShow | Equities.com |

What's the drug giant been up to?


Tax Reform Uncertainty Dampening Biotech M&A

Edward Kim | Equities.com |

Lowest level of biotech M&A activity in 4 years.


Sponsored Financial Content

Market Movers